ALECENSARO (alectinib) received approval from Health Canada as a monotherapy for the treatment of patients with anaplastic lymphoma kinase-positive, locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib. The drug is marketed under the name Alecensa in the US. The drug, which...
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
